Table 2.
Raw and Adjusted Comparisons of Factors of Interest for XR-BUP Between Incarcerated and Non-Incarcerated Subjects
| Parameter | OR [95% CI] | aOR [95% CI] a |
|---|---|---|
| Binarized answers to Q.38. “In your opinion, what are the important points that could lead you to choosing this new treatment (ie XR-BUP)?” | ||
| No longer having to take any tablets (or capsules/syrup) every day (nmv= 2) | ||
| Incarcerated (n= 96; 30.1%) | 1.76 [0.99–3.14] † | 1.81 [0.99–3.31] † |
| Not incarcerated (n= 223; 69.9%) | 1 | 1 |
| No longer forgetting to take the tablets (or capsules/syrup) (nmv= 5) | ||
| Incarcerated (n= 96; 30.4%) | 0.91 [0.56–1.48] | 0.87 [0.52–1.44] |
| Not incarcerated (n= 220; 69.6%) | 1 | 1 |
| The option of taking the medication only once a week/month (nmv= 6) | ||
| Incarcerated (n= 95; 30.2%) | 1.22 [0.66–2.26] | 1.25 [0.65–2.4] |
| Not incarcerated (n= 220; 69.8%) | 1 | 1 |
| The fact that a subcutaneous injection is involved (only slightly painful) (nmv= 3) | ||
| Incarcerated (n= 96; 30.2%) | 0.26 [0.15–0.46] ** | 0.24 [0.14–0.43] ** |
| Not incarcerated (n= 222; 69.8%) | 1 | 1 |
| Being sure to receive a constant dose, always effective throughout the week/month (nmv= 3) | ||
| Incarcerated (n= 96; 30.2%) | 3.11 [1.27–7.64] * | 2.91 [1.21–6.98] * |
| Not incarcerated (n= 222; 69.8%) | 1 | 1 |
| No longer having to use heroin/morphine (nmv= 3) | ||
| Incarcerated (n= 96; 30.2%) | 0.72 [0.41–1.28] | 0.67 [0.36–1.24] |
| Not incarcerated (n= 222; 69.8%) | 1 | 1 |
| Avoiding having to share (or resell) all or part of my prescribed treatment (nmv= 4) | ||
| Incarcerated (n= 96; 30.3%) | 0.70 [0.43–1.14] | 0.70 [0.42–1.17] |
| Not incarcerated (n= 221; 69.7%) | 1 | 1 |
| No longer worrying about feeling ill if I forget my treatment for a few hours, or if I am unable to take it at the usual time (nmv= 5) | ||
| Incarcerated (n= 96; 30.4%) | 0.56 [0.32–0.99] * | 0.54 [0.29–0.99]* |
| Not incarcerated (n= 220; 69.6%) | 1 | 1 |
| No longer feeling the effect of heroin/morphine if I take more of this treatment than I should (nmv= 10) | ||
| Incarcerated (n= 93; 29.9%) | 0.61 [0.38–0.99] * | 0.62 [0.37–1.03] † |
| Not incarcerated (n= 218; 70.1%) | 1 | 1 |
| No longer having the option of injecting, snorting or inhaling my treatment (nmv= 6) | ||
| Incarcerated (n= 96; 30.5%) | 0.59 [0.36–0.96] * | 0.56 [0.34–0.94] * |
| Not incarcerated (n= 219; 69.5%) | 1 | 1 |
| The option of a more “discreet” treatment (one injection a week/month by going to my doctor’s/to the centre) as compared to tablets (or capsules, syrup) to be taken at home, with me, every day (nmv= 4) | ||
| Incarcerated (n= 96; 30.3%) | 1.98 [1.15–3.41] * | 1.76 [1.01–3.10] * |
| Not incarcerated (n= 221; 69.7%) | 1 | 1 |
| Binarized answers to Q.39. “Would you say that for you this new product (ie XR-BUP) involves” | ||
| Fewer limitations compared to your current treatment (nmv= 3) | ||
| Incarcerated (n= 96; 30.2%) | 1.54 [0.85–2.79] | 1.44 [0.78–2.68] |
| Not incarcerated (n= 222; 69.8%) | 1 | 1 |
| The option of better following/adhering to my treatment, avoiding cravings and relapses (nmv= 3) | ||
| Incarcerated (n= 96; 30.3%) | 1.29 [0.75–2.21] | 1.42 [0.81–2.47] |
| Not incarcerated (n= 221; 69.7%) | 1 | 1 |
Note: †p<0.1; *p<0.05; **p<0.0001. Significant OR or aOR (p-value) are presented in bold. (aadjusted for gender, age category, level of education, and type of OAT).
Abbreviations: OR, odds ratio; aOR, adjusted OR; 95% CI: 95% confidence interval; nmv, number of missing values; XR-BUP, extended-release buprenorphine.